How do you rebuild confidence after long delays in drug development? We helped a new management team reintroduce the company and its strategy. Through high-impact messages, graphics and events, we helped people understand the science, burden of disease, clinical evidence, and path forward.


Bioblast Pharma Ltd. is a clinical-stage, orphan disease-focused biotechnology company with a newly restructured management team, a promising platform technology, and a dynamic, emerging pipeline. Bioblast sought to communicate its renewed dedication to the rare disease community by clearly presenting the data to current and potential investors.

  • Restore trust with all key stakeholders from investors to patients to physicians
  • Introduce new management team with proven track record in orphan drug development
  • Capture burden of disease and potential benefits to patients and their families
  • Show clinical, commercial potential of the company’s platform technology across multiple diseases
  • Build investor confidence in pipeline moving forward and help attract capital



Our work:

  • Developed new corporate, pipeline and product messages to reflect recent changes and growth within the company
  • Redesigned corporate presentation, both from a content and design standpoint
  • Created high-impact tools to explain the science and the business strategy:
    • Medical illustration to demonstrate the platform technology’s mechanism of action
    • Educational graphic to depict the complex symptoms of the disease
    • Biography booklet to inform audience members about the speakers
  • Conducted outreach to members of disease community; letter to patients, families and advocates


  • Attracted 37 investors to attend in-person
  • Secured 50 participants via webcast
  • Developed clear, focused messages to re-introduce the company, explain the science and demonstrate the potential of the Bioblast’s platform technology
  • Led to development of new corporate website to align with corporate branding and message